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Abstract
Background: Neurological disorders are a common cause of morbidity and mortality within Pakistani populations.
It is one of the most important challenges in healthcare, with significant life-long socio-economic burden.
Methods: We investigated the cause of disease in three Pakistani families in individuals with unexplained
autosomal recessive neurological conditions, using both genome-wide SNP mapping and whole exome
sequencing (WES) of affected individuals.
Results: We identified a homozygous splice site variant (NM_000521:c.445 + 1G > T) in the hexosaminidase B (HEXB)
gene confirming a diagnosis of Sandhoff disease (SD; type II GM2-gangliosidosis), an autosomal recessive lysosomal
storage disorder caused by deficiency of hexosaminidases in a single family. In two further unrelated families, we
identified a homozygous frameshift variant (NM_024298.3:c.758_778del; p.Glu253_Ala259del) in membrane-bound
O-acyltransferase family member 7 (MBOAT7) as the likely cause of disease. MBOAT7 gene variants have recently
been identified as a cause of intellectual disability (ID), seizures and autistic features.
Conclusions: We identified two metabolic disorders of lipid biosynthesis within three Pakistani families presenting
with undiagnosed neurodevelopmental conditions. These findings enabled an accurate neurological disease
diagnosis to be provided for these families, facilitating disease management and genetic counselling within this
population. This study consolidates variation within MBOAT7 as a cause of neurodevelopmental disorder, broadens
knowledge of the clinical outcomes associated with MBOAT7-related disorder, and confirms the likely presence of a
regionally prevalent founder variant (c.758_778del; p.Glu253_Ala259del) in Pakistan.
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Background
Neurological disorders cause structural, functional, bio-
chemical or electrical abnormalities in the nervous sys-
tem, resulting in cognitive impairment, seizures, muscle
weakness, paralysis, poor coordination and mood alter-
ation. Neurological disorders are an increasing burden in
developing countries due to improving life expectancy,
urbanisation of the population and improved health care
and diagnosis. A higher prevalence of intellectual disabil-
ity (ID) and epilepsy have been identified within
Pakistani populations compared with more economically
developed countries [1, 2]. In Pakistan, 82.5% of the par-
ents are blood relatives due to religious, economic, social
and cultural reasons in different regions [3]. The HEXB
gene encodes the hexosaminidase beta subunit, which
forms a heterodimer with the alpha subunit in hexosa-
minidase A (HEXA) and a homodimer in hexosamini-
dase B (HEXB), which are important enzymes within
neuronal membrane components responsible for GM2
ganglioside degradation. Sandhoff disease (SD)(MIM
268800) is an autosomal recessive lysosomal lipid storage
disorder caused by biallelic variants within the HEXB
gene, resulting in deficiency of HEXA and HEXB en-
zymes [4] and intralysosomal accumulation of GM2
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ganglioside and related glycolipids within neurons. This
leads to progressive destruction of the central nervous
system (CNS); classical onset of SD occurs with onset of
symptoms before 6 months of age of progressive psycho-
motor retardation, motor weakness, hyperreflexia, early
blindness with cherry red spots, macrocephaly, and with
death occurring by 3–5 years [5].
Recently homozygous pathogenic variants within
MBOAT7 have been identified in 16 families (15 consan-
guineous and 1 reported as non-consanguineous, al-
though both parents were from the same village in
Lebanon) as a cause of a neurodevelopmental disorder
(autosomal recessive mental retardation type 57 (MIM
617188) characterized by seizures, moderate to severe ID
with significant psychomotor retardation (several indi-
viduals are non-verbal and never walked, usually occur-
ring with seizure onset), truncal hypotonia, appendicular
hypertonia, features of autism spectrum disorder (ASD),
below average head circumference and characteristic fa-
cial features [6–10]. The MBOAT protein family consists
of five acyltransferases; lysophosphatidylinositol acyl-
transferase 1 (LPIAT1) encoded by the MBOAT7 gene is
known to transfer arachidonic acid (AA) from
arachidonoyl-CoA to lysophosphatidylinositol [11]. Only
one other MBOAT gene has been linked to human dis-
ease of brachydactyly-syndactyly syndrome in a single
patient with a balanced translocation disrupting
MBOAT1 [12].
In the present study, we investigate three consanguin-
eous Pakistani families with features of autosomal reces-
sive neurological disorders in order to identify a precise
molecular diagnosis using a combination of genome wide
SNP mapping and whole exome sequencing (WES).
Methods
Ethics approval and consent to participate
This study was approved by the Institutional Ethical Re-
view Board of International Islamic University, Islamabad,
Pakistan. Written informed consent to participate was ob-
tained from all individuals in the study or their parents.
Three families were recruited to the study from re-
mote regions of Khyber Pakhtunkhwa (KP) province of
Pakistan. Available affected and unaffected members of
all families underwent clinical examination at local gov-
ernment hospitals with review of relevant medical re-
cords and blood samples were taken with informed
consent.
Genomic analysis
Venous blood samples were collected in EDTA tubes
(BD, Franklin Lakes, NJ, USA) from 15 individuals
(shown with asterisks; Fig. 1) and DNA was extracted
Fig. 1 a Pedigree of family 1, with two affected siblings with Sandhoff disease (filled symbols). Genotype is shown in red under individuals (+,
mutant; −, WT). * indicates samples available for analysis. The affected female was shown to be homozygous for the HEXB c.445 + 1G > T splice
site variant. b Electropherogram showing the DNA sequence variant (HEXB c.445 + 1G > T) in a homozygous affected individual. c Schematic
representation of HEXB exons and position of the genomic variant identified in this study. d-e Pedigrees of families 2 and 3, both from the
Khyber Pakhtunkhwa province and with individuals affected with a neurodevelopmental disorder (filled symbols), within the same generation.
Genotype is shown in red under individuals (+, mutant; −, WT). * indicates samples available for analysis. Six affected individuals were shown to
be homozygous for the MBOAT7 c.758_778del; p.(Glu253_Ala259del) variant (f) Electropherogram showing the DNA sequence variant (MBOAT7
c.758_778del; p.(Glu253_Ala259del) in a homozygous affected individual (g) Schematic representation of MBOAT7 exons and positions of the
genomic variant identified in this study
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using the GenElute™ Blood Genomic DNA Kit (Merck)
according to the manufacturer’s protocols and quantifi-
cation using standard methods. WES was undertaken on
DNA from a single affected individual of family A (IV-2)
using the Agilent 2100 Bioanalyser/Illumina HiSeq2000
platform and exome enrichment was performed using
SureSelect Human All ExonV4 (51Mb) with a mean
read depth of 30X. Reads were aligned (BWA-MEM),
mate-pairs fixed and duplicates removed (Picard), inDel
realignment and base quality recalibration performed
(GATK). SNVs and InDels were detected using GATK
HaplotypeCaller and custom annotation was performed
using standard DNAnexus (DNAnexus Inc., Mountain
View, CA; https://dnanexus.com). Data was filtered to
identify rare non-synonymous exonic or splice variants,
with a population frequency of < 0.01 in control data-
bases (including the Genome Aggregation Database;
gnomAD, the Exome Aggregation Consortium; ExAC,
and the 1000 Genomes Project), and analysed consider-
ing the disease phenotype. Single-nucleotide polymorph-
ism (SNP) genotyping was performed (HumanCytoSNP-
12 v2.1 beadchip array, Illumina) in 3 affected individ-
uals in family B. In silico prediction of variant pathogen-
icity was assessed using FATHMM (http://fathmm.
biocompute.org.uk/), MutationTaster (http://www.muta-
tiontaster.org/), Varsome (https://varsome.com/), DaNN
(https://omictools.com/dann-tool), NNSplice (Berkeley,
CA, USA), MutPred Splice (v1.3.2), MaxEnt, SKIPPY
and Human Splice Finder (v2.4.1). Allele-specific
primers were designed using Primer3 web software
(http://frodo.wi.mit.edu/primer3/). PCR and dideoxy se-
quencing were performed using standard methods to
confirm cosegregation of candidate variants.
Results
Clinical findings
Family 1
A single affected female (IV-4) was the fourth child born
to a consanguineous Pakistani couple (Fig. 1a), reported
to have a severe seizure phenotype, poor vision, and pro-
found psychomotor retardation (Table 1). Parents re-
ported an uneventful antenatal, birth and neonatal
history, with normal early development. An ocular
phenotype of strabismus with nystagmus were the first
symptoms described by the parents around 5 months of
age. Onset of generalised tonic-clonic (GTC) seizures
with excessive startle reflex were observed at 7 months
of age with increasing frequency and severity over time,
although control was improved after the introduction of
phenobarbital. At 1 year of age loss of visual fixation was
the earliest sign of regression. Over time further loss of
vision, hearing, speech and motor skills progressed with
loss of independent sitting and head control and no re-
sponse to any stimuli by 18months, associated with
increased GTC seizure frequency. An older male sibling
(IV-2) was reported by the parents to have died at the
age of 18 months with a similar neurodegenerative
phenotype.
Family 2
Family 2 comprises five affected individuals (IV-3, IV-4,
IV-5, IV-6 and IV-7) with global developmental delay,
moderate to severe ID, hypotonia and behavioural prob-
lems, including aggression and hyperactivity (Table 1),
in a large consanguineous (parents are first-cousins)
Pakistani family (Fig. 1d) from Mardan city, a remote re-
gion of Khyber Pakhtunkhwa province of Pakistan. Two
brothers (IV-3 and IV-4) had infantile focal and multi-
focal epilepsy with seizure onset at 1.5 and 2.5 years re-
spectively, which has been responsive to antiepileptic
medication. Furthermore, three affected individuals (IV-
5, IV-6 and IV-7) developed febrile seizures in infancy.
All subjects have a below average head size (Table 1),
and one individual has microcephaly (IV-3); MRI brain
imaging of this individual revealed mild diffuse cerebral
atrophy with no sulcal prominence or ventricular
enlargement.
Family 3
This family comprises two affected siblings (IV-1 and
IV-2) with microcephaly, GTC seizures from infancy,
moderate to severe ID, global developmental delay, in-
cluding absent speech, poor memory, and behavioural
problems including aggressive episodes and hyperactivity
(Table 1), who were born to a consanguineous Pakistani
couple (Fig. 1e) from Swat city of the Khyber Pakh-
tunkhwa province of Pakistan. An EEG performed on in-
dividual IV-1 at the age of 3 years showed a mixed
background rhythm of beta and theta waves, with abnor-
mal bursts of sharp waves and generalized slow waves
on arousal from sedation. MRI brain imaging of this in-
dividual (IV-1) shows regions of cortical atrophy, cor-
onal T2 image shows cortical thinning and loss of
underlying white matter leading to enlarged fissures in
the vermis and cerebellar hemispheres.
Genetic findings
WES was performed using DNA from a single affected
individual (IV-2) from family 1, after filtering variants
for quality, zygosity, population frequency and predicted
outcome, a single homozygous splice site variant (chr5:
g.74689474G > T; c.445 + 1G > T [rs761197472]) was
identified in HEXB (NM_000521, a gene previously asso-
ciated with an autosomal recessive neurodegenerative
disorder, for filtering steps in variant prioritization).
Dideoxy sequencing confirmed cosegregation of this
variant within Family 1 (Fig. 1a, b). This HEXB splice
variant c.445 + 1G > T is predicted to affect the canonical
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splicing of exon 2 by abolishing the normal 5′ donor
splice site, which is predicted to likely result in skipping
of exon 2, and possibly promotes the use of a cryptic
splice site upstream of the intronic 5′ donor sequence
(Fig. 1c). This rare variant is present as heterozygous in
a single South Asian individual in gnomAD (allele fre-
quency 0.00003266), with no homozygous individuals. A
splice variant at the same position (c.445 + 1G > A) has
previously been published as a cause of disease in several
patients from Argentinian families with SD [13–15] and
is reported as pathogenic in ClinVar and the HGMD
database. A further splice variant at this position
(c.445 + 1G > C) is also listed in ClinVar and dbSNP with
conflicting interpretations of pathogenicity.
Genome-wide SNP-array genotyping of DNA from
affected individuals IV-3, IV-4 and IV-7 identified a
single 1.7 Mb region of shared homozygosity between
the affected individuals from rs465169 to rs2112834
(chr19: 54,023,718-55,785,242 [hg38], containing 82
protein coding genes. Of these genes only 9 had
OMIM morbid phenotypes: DNAAF3, GP6, KIR3DL1,
MBOAT7, NLRP7, PRPF31, TNNI3, TNNT1 and
TSEN34 and only two had associated neurological
phenotypes compatible with that of affected individ-
uals within this family: TSEN34 [16] and MBOAT7 [7].
MBOAT7 variant assessment was prioritized as more
literature has been reported on the phenotype associ-
ated with this gene, including two recently published
variants identified within Pakistani families [7]
(Table 2). Dideoxy sequencing of MBOAT7 (NM_
024298.3) using primers that cover both previously
identified variants within the Pakistani population
(c.820_826del p.(Gly274Profs*47) and c.758_778del;
p.(Glu253_Ala259del)), revealed the 21 base pair in-
frame deletion (Chr19:g.54180849_54180869del21;
c.758_778del; p.(Glu253_Ala259del) [hg38]
[rs750035706]) in exon 6 that cosegregated in family 2
(Fig. 1d, f-g). Due to an overlapping phenotype and
common origin of families 2 and 3, we performed
dideoxy sequencing for the c.758_778del MBOAT7
variant in family 3, which confirmed cosegregation
(Fig. 1e). The MBOAT7 c.758_778del variant is re-
ported in gnomAD in 5 heterozygous individuals,
(four South Asian and one Finnish), with an allele fre-
quency of 0.00002333 (0.0001571 in the South Asian
population), and is listed in Clinvar and dbSNP as
pathogenic. This variant results in loss of seven highly
conserved amino acids (p.Glu253_Ala259del)
[rs750035706] from the MBOAT7 protein thus produ-
cing a shorter protein, and is predicted to be patho-
genic by in silico prediction tools. Neither of these
identified variants in HEXB (c.445 + 1G > T) and
MBOAT7 (c.758_778del) were present in 65 Pakistani
exomes of unaffected individuals.
Discussion
We investigated three extended consanguineous Paki-
stani families with individuals affected by undiagnosed
childhood onset neurological disease, aiming to provide
an accurate molecular diagnosis for these families. WES
in a single affected individual in family 1 identified a
homozygous splice variant (NM_000521; c.445 + 1G > T)
in HEXB that segregated within the family and confirms
a diagnosis of SD within this individual and her deceased
sibling. The clinical features reported in this patient, in-
cluding hypotonia, generalized tonic-clonic or myoclonic
seizures with regression, blindness, psychomotor retard-
ation, ID, macrocephaly, hepatosplenomegaly, and death
in infancy are consistent with previous reports of SD
[17, 18]. Many variants have been reported in HEXB as-
sociated with SD, including 116 pathogenic (DM) vari-
ants listed within the Human Gene Mutation Database
(HGMDpro, http://www.hgmd.cf.ac.uk/ac/index.php).
Disruption of the hexosaminidase beta subunit results in
a deficiency of the enzymes hexosaminidases A and B,
and results in the accumulation of GM2 ganglioside
within neurons that results in progressive destruction of
the CNS. This is the first description of the c.445 + 1G >
T variant that we are aware of within the Pakistani
population, although another splice variant at this pos-
ition (c.445 + 1G > A) has previously been reported in
Argentinian families with SD [13, 14].
Genome-wide SNP mapping was carried out using
DNA from all three affected individuals from family 2
and identified a 1.7Mb region of shared homozygosity
(chr19: 54,023,718-55,785,242 [hg38]). This region in-
cludes the MBOAT7 gene, recently reported by Johansen
et al. (2016) [7] to be associated with a neurodevelop-
mental phenotype characterised by developmental delay/
ID seizures, hypotonia, autistic features and below aver-
age head size. This group reported two different homo-
zygous variants in MBOAT7 within three
consanguineous Pakistani families; a 7 bp frameshift de-
letion (c.820_826del [p.Gly274Profs*47]) in exon 6 in
four affected individuals from a single family, and an in-
frame deletion (c.758_778del [p.Glu253_Ala259del]) also
in exon 6 in five affected individuals from two unrelated
families. We identified the same 21 base pair in-frame
deletion (c.758_778del; p.Glu253_Ala259del) in families
2 and 3, which cosegregated as appropriate for an auto-
somal recessive condition. Our findings in these families
are consistent with the clinical features described previ-
ously (Tables 1 and 3), confirming a diagnosis of an
MBOAT7-associated disorder in the patients presented
here.
This study adds seven affected individuals from two
Pakistani families to the literature, with a total of 43 in-
dividuals now described with biallelic pathogenic
MBOAT7 variants and similar overlapping phenotypes
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(Table 3). A total of 13 MBOAT7 variants associated
with autosomal recessive neurodevelopmental disorder
have been described to date (Table 2); nine of which are
truncating and loss-of-function variants and not toler-
ated in gene constraint predictions with a pLI score of
0.113 in gnomAD. A total of 12 individuals from four
consanguineous Pakistani families with a similar neuro-
developmental phenotype have now been reported as
homozygous for the MBOAT7 c.758_778del variant
(Table 2). The further two families reported here
Table 3 Clinical features of all published cases associated with biallelic MBOAT7 variants
Publications Current
study
Johansen et al
[7]
Hu et al
[9]
Santos-Cortez et al
[8]
Yalnizoglu et al
[6]
Jacher et al
[10]
Total (n = 39)
Sex M = 4, F = 3 M = 7, F = 9 M = 3, F =
0
M = 2, F = 2 M = 5, F = 7 M = 0, F = 1 M = 21, F =
22
Consanguinity 7/7 (100%) 16/16 (100%) 3/3 (100%) 4/4 (100%) 12/12 (100%) 0/1 (0%) 42/43 (98%)
Development
Developmental delay 7/7 (100%) 16/16 (100%) 0/3 (0%) 4/4 (100%) 12/12 (100%) 1/1 (100%) 40/43 (93%)
Speech delay 7/7 (100%) 16/16 (100%) 0/3 (0%) 4/4 (100%) 12/12 (100%) 1/1 (100%) 40/43 (93%)
Non-verbal 5/7 (71%) 9/16 (56%) 0/3 (0%) N/K N/K 0/1 (0%) 14/27 (52%)
Single words 2/7 (29%) 7/16 (44%) N/K N/K N/K 1/1 (100%) 10/24 (42%)
Two word sentences 0/7 (0%) 2/16 (13%) N/K N/K 3/12 (25%) 1/1 (100%) 6/36 (17%)
Motor delay 7/7 (100%) 16/16 (100%) 0/3 (0%) N/K 12/12 (100%) 1/1 (100%) 36/39 (92%)
Never walked 0/7 (0%) 3/16 (19%) 0/3 (0%) N/K 0/12 (0%) 0/1 (0%) 3/39 (8%)
Neurological features
Intellectual disability 7/7 (100%) 16/16 (100%) 3/3 (100%) 4/4 (100%) 12/12 (100%) 1/1 (100%) 43/43 (100%)
Lower than average OFC 7/7 (100%) 16/16 (100%) 0/3 (0%) 4/4 (100%) N/K 0/1 (0%) 27/31 (87%)
Microcephaly 2/7 (29%) 6/16 (38%) 0/3 (0%) 2/4 (50%) N/K 0/1 (0%) 10/31 (32%)
Macrocephaly 0/7 (0%) 0/16 (0%) 0/3 (0%) 0/4 (0%) 0/7 (0%) 1/1 (100%) 1/43 (2%)
Seizures 6/7 (86%) 10/16 (63%) 3/3 (100%) N/K 11/12 (92%) 1/1 (100%) 31/39 (79%)
Generalised tonic clonic 0/7 (0%) 1/16 (6%) N/K N/K 2/12 (17%) 0/1 (0%) 3/36 (8%)
Myoclonic/infantile spasm 0/7 (0%) 5/16 (31%) N/K N/K 3/12 (25%) 0/1 (0%) 8/36 (22%)
Focal 2/7 (29%) 2/16 (13%) N/K N/K 1/12 (8%) 1/1 (100%) 6/36 (17%)
Febrile seizures 2/7 (29%) 2/16 (13%) N/K N/K 1/12 (8%) 0/1 (0%) 5/36 (14%)
Hypotonia 6/7 (86%) 15/16 (94%) N/K N/K 12/12 (100%) 1/1 (100%) 34/36 (94%)
Hypertonia 0/7 (0%) 16/16 (100%) N/K N/K 0/12 (0%) 0/1 (0%) 16/36 (44%)
Behavioural problems/ASD 3/7 (43%) 7/16 (44%) 3/3 (100%) N/K 4/12 (33%) 1/1 (100%) 18/39 (46%)
Poor coordination/ataxic
gait
0/7 (0%) 0/16 (0%) N/K N/K 11/12 (92%) N/K 11/35 (31%)
Neuroimaging 1/7 (14%) 6/16 (38%) 1/3 (33%) N/K 12/12 (100%) 1/1 (100%) 21/39 (54%)
Polymicrogyria 0/1 (0%) 2/6 (13%) 0/3 (0%) N/K 0/12 (0%) 0/1 (0%) 2/23 (9%)
Cortical atrophy 1/1 (100%) 2/6 (13%) 0/3 (0%) N/K 8/12 (67%) 0/1 (0%) 11/23 (45%)
Cerebellar dysgenesis 0/1 (0%) 0/6 (0%) 0/3 (0%) N/K 8/12 (67%) 0/1 (0%) 8/23 (35%)
Leukoencepahlopathy 0/1 (0%) 0/6 (0%) 1/1 (100%) N/K 0/12 (0%) 1/1 (100%) 2/21 (10%)
Other features
Strabismus N/K N/K 1/3 (33%) N/K 5/12 (42%) 1/1 (100%) 7/16 (44%)
Retinal/macular
degeneration
0/12 (0%) N/K 2/3 (67%) N/K N/K 0/1 (0%) 2/16 (13%)
Optic atrophy 0/12 (0%) N/K 3/3 (100%) N/K N/K 0/1 (0%) 3/16 (19%)
Hyperphagia/obesity 0/12 (0%) N/K 3/3 (100%) N/K N/K 1/1 (100%) 4/16 (25%)
Short stature 3/7 (43%) N/K 0/3 (0%) N/K N/K 0/1 (0%) 3/11 (27%)
Comparison of clinical features of all published cases of neurological disorder associated with biallelic MBOAT7 variants, showing number and percentage of
individuals (in brackets) with each feature. OFC occipitofrontal circumference, ASD autistic spectrum disorder, N/K not known
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contribute to knowledge of the phenotypical spectrum
of neurological disorder associated with disruption of
MBOAT7, characterised by the universal feature of
moderate to severe ID, usually associated with significant
global developmental delay, profound speech impair-
ment (52% are non-verbal), motor delay (8% never walk)
and lower than average OFC (32% have microcephaly)
(Table 3). Other frequent features are seizures in 79%,
including GTC, myoclonic, infantile spasm, focal and
multifocal seizures, hypotonia is reported in 94% (often
described as truncal hypotonia in infancy), hypertonia is
also reported in 44%, autistic features and behavioral
problems include aggressive episodes, hyperactivity, ste-
reotypies (rocking and hand flapping) in 46%. Jacher
et al. [10] reported macrocephaly with overgrowth in a
single patient, although macrocephaly has not been ob-
served in any other previously reported cases. While we
cannot exclude additional genetic or environmental
causes our data suggest that short stature (below − 3 SD
identified in 3/5 individuals) may also be a feature of
MBOAT7-related disorder. MRI imaging identified sev-
eral common findings of cortical atrophy in 45%, cere-
bellar dysgenesis in 35%, leukocencepahlopathy in 10%
and polymicrogyria in 9% of individuals who underwent
imaging and as previously discussed by Yalnizoglu et al
[6], these findings are common to other complex lipid
biosynthesis and remodeling disorders.
The MBOAT7 gene encodes LPIAT1, an enzyme
present in endomembranes that contributes to the regu-
lation of free arachidonic acid (AA) in the cell through
the remodeling of phospholipids via the Land’s cycle [19,
20]. Lee et al. [18] discovered that LPIAT1 is required
for cortical lamination in Mboat7−/− mice and brain
histology of these mice showed a smaller cerebral cortex,
with increased apoptotic cells and increased gyral struc-
tures. These findings are comparable with the phenotype
observed in humans of cortical atrophy, reduced head
size and polymicrogyria. Interestingly, Mboat7−/− mice
show significantly smaller stature than their wildtype lit-
termates [21], and is a feature that we have identified in
our patient cohort with 3/5 individuals with height < − 3
SD below the mean, confirming this as a novel feature
associated with MBOAT7-related neurodevelopmental
disorder.
Conclusions
Interestingly both protein products of MBOAT7 and
HEXB genes are involved in metabolic disorders of lipid
biosynthesis and remodeling within the brain, and this
group of disorders are an important and often over-
looked consideration in the differential diagnosis of neu-
rodevelopmental disorders [22]. Investigation and
identification of the genetic basis of neurodevelopmental
disorders identified within the three Pakistani families
reported here provide us with a better understanding of
the spectrum of neurological disease and responsible
gene variants present within this population to aid diag-
nosis in other families who may be affected by these
conditions. Accurate molecular disease diagnosis allows
a specific diagnosis to be provided to families and their
clinicians to provide targeted management strategies, ap-
propriate genetic counselling, improved carrier detection
and the possibility of prenatal testing where available.
Our findings highlight the MBOAT7 c.758_778del vari-
ant as a cause of developmental delay/ID in the Pakistani
population, and broaden knowledge of the phenotypical
outcomes associated with MBOAT7 gene variants.
Abbreviations
AA: Arachidonic acid; ExAC: Exome Aggregation Consortium;
GM2: Gangliosidases; GnomAD: Genome Aggregation Data base;
GTCS: Generalized tonic clonic seizure; HEXA: Hexosaminadase A;
HEXB: Hexosaminadase B; HGMD: Human gene mutation data base;
HOM: Homozygous; ID: Intellectual disability; LPIAT1: Lysophosphatidyl
inositol aceyl transferase 1; MBOAT7: Membrane bound O-aceyltransferase
family member 7; MRI: Magnetic Resonance Imaging; SD: Sandhoff disease;
SNP: Single Nucleotide Polymorphism; WES: Whole Exome Sequencing
Acknowledgments
The authors would like to thank the Pakistani families for their participation
in the research study.
Author’s contributions
SK, AU, and MJ recruited families and collected/compiled clinical information
with help of LER, ELB and AHC. SK, GVH, and MU, performed genetic studies,
and analyzed data alongside GVH, AHC, WA, LER, AG, AU, ELB, Manuscript
writing and revision: SK, LER, GVH, MU, SS, ELB, AHC, AH and AG. Study
supervision and coordination: ELB, AHC, and AG. The final version of the
manuscript was read and approved by all authors.
Funding
Shazia Khan was supported by International Research Support Initiative
Program (IRSIP) from HEC, Islamabad, Pakistan a. The funding body played
no role in the design of the study and collection, analysis, and interpretation
of data and in writing the manuscript.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study was approved by the Institutional Review Boards of International
Islamic University, Islamabad, Pakistan and University of Exeter, UK, in
accordance with Declaration of Helsinki protocols. Written informed consent
to participate was obtained from all individuals (or those with parental
responsibility).
Consent for publication
Written informed consent for publication of research findings was obtained
from all individuals (or those with parental responsibility) who participated in
the study.
Competing interests
Wasim Ahmad is a member of the editorial board (Associate Editor) of BMC
Medical Genetics. The remaining authors declare that they have no
competing interests.
Author details
1Department of Biological Sciences, International Islamic University
Islamabad, H-10, Islamabad 44000, Pakistan. 2Medical Research, RILD
Wellcome Wolfson Centre (Level 4), Royal Devon and Exeter NHS Foundation
Khan et al. BMC Medical Genetics          (2019) 20:199 Page 8 of 9
Trust, Exeter, Devon EX2 5DW, UK. 3Department of Biochemistry, Faculty of
Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan. 4Peninsula
Clinical Genetics Service, Royal Devon & Exeter Hospital (Heavitree),
Gladstone Road, Exeter EX1 2ED, UK. 5Rajarshi Shahu College of Pharmacy,
Malvihir Buldana, Maharashtra, Buldana 443001, India. 6Medical Genomics
Research Department, King Abdullah International Medical Research Center
(KAIMRC), King Saud bin Abdulaziz University for Health Sciences, Ministry of
National Guard–Health Affairs (MNGHA), P.O. Box 3660, Riyadh 11481,
Kingdom of Saudi Arabia. 7Department of Molecular Biology, Shaheed
Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan. 8National Institute
for Genomics & Advanced Biotechnology, NARC, Islamabad 45500, Pakistan.
Received: 22 May 2019 Accepted: 15 October 2019
References
1. Durkin MS, Hasan ZM, Hasan KZ. Prevalence and correlates of mental
retardation among children in Karachi, Pakistan. Am J Epidemiol. 1998;
147(3):281–8.
2. Khatri IA, Iannaccone ST, Ilyas MS, Abdullah M, Saleem S. Epidemiology of
epilepsy in Pakistan: review of literature. J Pak Med Assoc. 2003;53(12):594–7.
3. Ahmad F, Bilal M, Khan A, Umair M. Genetic skeletal disorders in Pakistan: A
brief commentary. Meta Gene. 2019;20:100559. https://doi.org/10.1016/j.
mgene.2019.100559.
4. Sandhoff K, Andreae U, Jatzkewitz H. Deficient hexosaminidase activity in an
exceptional case of Tay-Sachs disease with additional storage of kidney
globoside in visceral organs. Pathol Eur. 1968;3(2):278–85.
5. Hendriksz CJ, Corry PC, Wraith JE, Besley GT, Cooper A, Ferrie CD. Juvenile
Sandhoff disease--nine new cases and a review of the literature. J Inherit
Metab Dis. 2004;27(2):241–9.
6. Yalnızoǧlu D, Özgül RK, Oǧuz KK, Özer B, Yücel-Yılmaz D, Gürbüz B, et al.
Expanding the phenotype of phospholipid remodelling disease due to
MBOAT7 gene defect. J Inherit Metab Dis. 2019;42(2):381–8.
7. Johansen A, Rosti RO, Musaev D, Sticca E, Harripaul R, Zaki M, et al.
Mutations in MBOAT7, encoding Lysophosphatidylinositol Acyltransferase I,
Lead to intellectual disability accompanied by epilepsy and autistic features.
Am J Hum Genet. 2016;99(4):912–6.
8. Santos-Cortez RLP, Khan V, Khan FS, Mughal ZU, Chakchouk I, Lee K, et al.
Novel candidate genes and variants underlying autosomal recessive
neurodevelopmental disorders with intellectual disability. Hum Genet. 2018;
137(9):735–52.
9. Hu H, Kahrizi K, Musante L, Fattahi Z, Herwig R, Hosseini M, et al. Genetics of
intellectual disability in consanguineous families. Mol Psychiatry. 2019;24(7):
1027–1039. https://doi.org/10.1038/s41380-017-0012-2. Epub 2018 Jan 4.
10. Jacher JE, Roy N, Ghaziuddin M, Innis JW. Expanding the phenotypic
spectrum of MBOAT7-related intellectual disability. Am J Med Genet B
Neuropsychiatr Genet. 2019;180(7):483–487. https://doi.org/10.1002/ajmg.b.
32749. Epub 2019 Jul 8.
11. Lee HC, Inoue T, Imae R, Kono N, Shirae S, Matsuda S, et al. Caenorhabditis
elegans mboa-7, a member of the MBOAT family, is required for selective
incorporation of polyunsaturated fatty acids into phosphatidylinositol. Mol
Biol Cell. 2008;19(3):1174–84.
12. Dauwerse JG, de Vries BB, Wouters CH, Bakker E, Rappold G, Mortier GR,
et al. A t(4;6)(q12;p23) translocation disrupts a membrane-associated O-
acetyl transferase gene (MBOAT1) in a patient with a novel brachydactyly-
syndactyly syndrome. Eur J Hum Genet. 2007;15(7):743–51.
13. Kleiman FE, de Kremer RD, de Ramirez AO, Gravel RA, Argaraña CE. Sandhoff
disease in Argentina: high frequency of a splice site mutation in the HEXB
gene and correlation between enzyme and DNA-based tests for
heterozygote detection. Hum Genet. 1994;94(3):279–82.
14. Brown CA, McInnes B, de Kremer RD, Mahuran DJ. Characterization of two
HEXB gene mutations in Argentinean patients with Sandhoff disease.
Biochim Biophys Acta. 1992;1180(1):91–8.
15. Zampieri S, Cattarossi S, Oller Ramirez AM, Rosano C, Lourenco CM, Passon
N, et al. Sequence and copy number analyses of HEXB gene in patients
affected by Sandhoff disease: functional characterization of 9 novel
sequence variants. PLoS One. 2012;7(7):e41516.
16. Budde BS, Namavar Y, Barth PG, Poll-The BT, Nürnberg G, Becker C, et al.
tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia.
Nat Genet. 2008;40(9):1113–8.
17. Sung AR, Moretti P, Shaibani A. Case of late-onset Sandhoff disease due to
a novel mutation in the. Neurol Genet. 2018;4(4):e260.
18. Gaignard P, Fagart J, Niemir N, Puech JP, Azouguene E, Dussau J, et al.
Characterization of seven novel mutations on the HEXB gene in French
Sandhoff patients. Gene. 2013;512(2):521–6.
19. Pérez-Chacón G, Astudillo AM, Balgoma D, Balboa MA, Balsinde J. Control of
free arachidonic acid levels by phospholipases A2 and lysophospholipid
acyltransferases. Biochim Biophys Acta. 2009;1791(12):1103–13.
20. Caddeo A, Jamialahmadi O, Solinas G, Pujia A, Mancina RM, Pingitore P,
et al. MBOAT7 is anchored to endomembranes by six transmembrane
domains. J Struct Biol. 2019;206(3):349–60. https://doi.org/10.1016/j.jsb.2019.
04.006.
21. Lee HC, Inoue T, Sasaki J, Kubo T, Matsuda S, Nakasaki Y, et al. LPIAT1
regulates arachidonic acid content in phosphatidylinositol and is required
for cortical lamination in mice. Mol Biol Cell. 2012;23(24):4689–700.
22. Garcia-Cazorla À, Mochel F, Lamari F, Saudubray JM. The clinical spectrum of
inherited diseases involved in the synthesis and remodeling of complex
lipids. A tentative overview. J Inherit Metab Dis. 2015;38(1):19–40.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Khan et al. BMC Medical Genetics          (2019) 20:199 Page 9 of 9
